EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, today provided an update on its commercial launch of Avenova™.
“We are encouraged by the market’s initial acceptance of Avenova,” said Ron Najafi, Ph.D., Chairman and CEO of NovaBay. “We spent most of third and fourth quarters of 2014 building our commercial infrastructure and training our newly formed 15 medical representative direct salesforce. As expected, revenue contribution from Avenova was modest, but we are optimistic based on the growth we experienced during this period.” NovaBay is reporting 2014 third quarter and fourth quarter sales for Avenova of approximately $90,000 and approximately $219,000, respectively.
Help employers find you! Check out all the jobs and post your resume.
